cardiac safety study of entinostat in men and women with advanced solid tumors

Conditions: Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Breast Neoplasms; Breast Diseases; Renal Neoplasm; Solid Tumors

Summary: the purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ecg) parameters. this study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and pharmacodynamic parameters.

this is a single center, randomized, placebo-controlled, single dosing schedule, double-blinded study to evaluate the effect of entinostat as compared to placebo on the electrical activity of the heart in patients with advanced solid tumors. thirty patients will be randomized in a 1:1 ratio to receive either entinostat or placebo. study treatment will be blinded to patients and the investigator. ecg analysts will be blinded to the patient, visit, and treatment allocation. patients will be on study up to 30 days following study drug administration. total study duration is expected to be 9 months. after completing this study and at the discretion of the investigator, patients may elect to enroll into a separate continuation study (sndx-275-0141).

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy(ies) or for which there is no approved therapy * patients must have acceptable laboratory requirements * left ventricular ejection fraction as measured by echocardiogram or multiple-gated acquisition scan that is above the institutional lower level of normal or greater than 50% * has experienced resolution of toxic effect(s) of the most recent prior chemotherapy and/or prior surgical and radiation treatment * must be able to understand and give written informed consent and comply with study procedures exclusion criteria: * if the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids * presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments * a medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the investigator * patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk * diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug * prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study * prior anti-cancer monoclonal antibody within 4 weeks prior to baseline * currently enrolled in another investigational study * has disease that is suitable for approved therapy administered with curative intent

Keywords: entinostat solid tumor histone deacetylase inhibitors